Ocular Therapeutix
OCUL
7.23
-0.11
-1.50%
Ocular Therapeutix
US · OCUL
#2978 by market cap
Listed 1970
7.23
-0.11
-1.50%
Live - 5344 symbols - heartbeat 248s ago
· 2026-10-08 08:27
Pre-market
7.32
+1.27%
After-hours
7.25
+0.28%
Overnight
7.18
-0.69%
- Market cap
- 1.59B
- P/E (TTM)i
- -5.16
- P/Bi
- 3.05
- EPSi
- -1.42
- Div yieldi
- 0.00%
- 52W posi
- 10%
Reader sentiment
Are you bullish or bearish on OCUL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- Total institutional ownership rose 0.4 percentage points.
Institutional ownership
- Held by institutions
- 95.06% +0.40pp
- Institutions
- 307
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund51.18%
Hedge Fund19.38%
VC/PE Fund15.05%
Family Office/Trust5.63%
Public Company2.09%
Individual/Insider1.20%
Private Company1.05%
Insurance Company0.41%
Government Pension Fund0.26%
Other3.75%
Top holders as of 2026-06-30
FMR
14.96% · 32.84M sh
Deep Track Capital, LP
8.96% · 19.69M sh
BlackRock
8.82% · 19.38M sh
Avoro Capital Advisors LLC
5.71% · 12.54M sh
Summer Road LLC
5.56% · 12.21M sh
VR Management, LLC
4.71% · 10.35M sh
Vanguard Capital Management, LLC
4.61% · 10.12M sh
T. Rowe Price Group, Inc.
3.47% · 7.62M sh
Logos Global Management, L.P.
2.41% · 5.30M sh
State Street Global Advisors
2.38% · 5.23M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 22 buys · 28 sells
| Name | Role | Stake |
|---|---|---|
| Pravin Dugel | Executive Chairperson | 0.36% |
| Antony Mattessich | Chief Executive Officer | 0.18% |
| Richard Lindstrom | Independent Director | 0.11% |
| Donald Notman | Chief Financial Officer | 0.08% |
| Sanjay Nayak | Chief Strategy Officer | 0.08% |
| Jeffrey Heier | Independent Director | 0.07% |
| Peter Kaiser | Chief Medical Advisor of Retina | 0.04% |
| Nadia Waheed | Chief Medical Officer | 0.04% |
| William Link | -- | 0.04% |
| Steve Meyers | Senior Vice President of Commercial | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | Jeffrey Heier | Independent Director | Intent to Sell (Form 144) | -10,869 | $7.05 |
| 2026-08-30 | Donald Notman | Chief Financial Officer | Open Market Disposition | -1,099 | $10.24 |
| 2026-08-24 | Pravin Dugel | Executive Chairperson | Other Acquisition | +50,092 | -- |
| 2026-08-24 | Pravin Dugel | Executive Chairperson | Other Disposition | -50,092 | -- |
| 2026-08-23 | Jeffrey Heier | Independent Director | Open Market Disposition | -3,296 | $10.78 |
| 2026-08-23 | Peter Kaiser | Chief Medical Advisor of Retina | Open Market Disposition | -3,035 | $10.77 |
| 2026-08-23 | Pravin Dugel | Executive Chairperson | Open Market Disposition | -21,649 | $10.77 |
| 2026-08-23 | Sanjay Nayak | Chief Strategy Officer | Open Market Disposition | -1,897 | $10.78 |
| 2026-06-15 | Pravin Dugel | Executive Chairperson | Other Acquisition | +50,092 | -- |
| 2026-06-15 | Pravin Dugel | Executive Chairperson | Other Disposition | -50,092 | -- |
| 2026-06-09 | William Link | -- | Other Acquisition | +14,000 | -- |
| 2026-06-09 | William Link | -- | Other Derivative Acquisition | +44,000 | $8.74 |
| 2026-06-09 | Merilee Raines | Independent Director | Other Acquisition | +14,000 | -- |
| 2026-06-09 | Merilee Raines | Independent Director | Other Derivative Acquisition | +44,000 | $8.74 |
| 2026-06-09 | Richard Lindstrom | Independent Director | Other Acquisition | +14,000 | -- |
| 2026-06-09 | Richard Lindstrom | Independent Director | Other Derivative Acquisition | +44,000 | $8.74 |
| 2026-06-09 | Adrienne Graves | Director | Other Acquisition | +14,000 | -- |
| 2026-06-09 | Adrienne Graves | Director | Other Derivative Acquisition | +44,000 | $8.74 |
| 2026-06-09 | Leslie Williams | Independent Director | Other Acquisition | +14,000 | -- |
| 2026-06-09 | Leslie Williams | Independent Director | Other Derivative Acquisition | +44,000 | $8.74 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:27:13 · For reference only, not investment advice and not tailored to your situation.